Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial - Bruix, J; Takayama, T; Mazzaferro, V (Lancet Oncol, 2015)
, et al; STORM investigators.